非破裂腹主动脉瘤腔内修复与开放修复的真实世界成本分析
基于美国Premier医疗数据库2009年7月至2015年3月登记的非破裂腹主动脉瘤患者,比较腔内修复(EVAR)与开放修复(OAR)的住院总成本。共纳入38,809例(EVAR 33,171例,OAR 5,638例),EVAR平均总成本低于OAR(32,052美元 vs 36,091美元,P < .001),但EVAR成本随时间显著增加而OAR保持稳定。
要点
- EVAR平均住院总成本低于OAR,主要因固定成本较低。
- 预期住院时长内OAR总成本反而低于EVAR。
- 2009至2014年EVAR平均总成本增加18.5%,OAR稳定。
核心结论
- 非破裂腹主动脉瘤EVAR的总体住院成本低于OAR。
- 在预期住院时长的患者中,OAR住院成本显著低于EVAR。
- OAR平均住院成本在研究5年内稳定,而EVAR成本随时间显著增加。
研究设计与样本
- 基于Premier医疗数据库的全国性、全支付方真实世界成本分析。
- 纳入2009年7月至2015年3月登记的非破裂腹主动脉瘤患者共38,809例(EVAR 33,171例,OAR 5,638例)。
- 采用t检验、χ2检验、Wilcoxon-Mann-Whitney秩和检验及方差分析比较成本。
主要发现
- EVAR平均总成本低于OAR(32,052美元 vs 36,091美元;P < .001)。
- EVAR固定成本低于OAR(11,309美元 vs 16,818美元;P < .001),可变成本高于OAR(20,743美元 vs 19,272美元;P < .001)。
- OAR的药品、人力、手术室、床位费等成本显著更高,EVAR耗材成本更高。
- 预期住院时长患者中,EVAR总成本高于OAR(27,271美元 vs 25,680美元;P < .001),可变成本也更高(18,186美元 vs 13,671美元;P < .001)。
- EVAR相关死亡病例成本高于OAR(72,483美元 vs 59,804美元;P = .017)。
临床怎么用
- 卫生经济学评估中需考虑EVAR成本随时间上升的趋势。
- 预期住院时长患者选择OAR可能降低住院成本。
- 需进一步研究明确EVAR成本增加的原因。
局限性
- 回顾性数据库分析,可能存在编码偏倚。
- 仅纳入Premier数据库登记患者,外推性受限。
- 成本仅覆盖住院期间,未包含远期成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to provide a nationwide, all-payer, real-world cost analysis of endovascular aortic aneurysm repair (EVAR) versus open aortic aneurysm repair (OAR) in patients with nonruptured abdominal aortic aneurysms (non-rAAA). METHODS: All non-rAAA patients registered between July 2009 and March 2015 in the Premier Healthcare Database were analyzed. The Student t-test and the χ2 test were used for continuous and categorical variables, respectively; median value comparisons were done with the Wilcoxon-Mann-Whitney rank-sum test. The in-hospital absolute mean total cost (sum of fixed cost and variable cost) and subcategories were analyzed after adjustment for inflation at July 2015. Fixed costs included all overhead costs while variables costs included in-hospital services including procedures, room and board, services provided by hospital staff, and pharmacy costs. Total cost was stratified based on admission type (emergency vs nonemergency), 75th percentile of length of hospital stay among individual procedures (expected vs extended stay), mortality, and complications. Student t-test and Fisher's analysis of variance were used for comparing mean cost. Year-wise comparison of mean cost was done with analysis of variance to look for a trend over time. RESULTS: Our study cohort included 38,809 non-rAAA patients (33,171 EVAR and 5638 OAR). The mean total cost of index admission was lower in EVAR in comparison with OAR ($32,052 vs $36,091; P < .001), with lower fixed costs ($11,309 vs $16,818; P < .001) and higher variable costs ($20,743 vs $19,272; P < .001). Cost of pharmacy, labor, operating room, room and board and other costs were significantly higher with OAR, whereas the supply cost was higher with EVAR. The expected hospital length of stay of patients who underwent EVAR was associated with a higher total cost ($27,271 vs $25,680; P < .001) and a higher variable cost ($18,186 vs $13,671; P < .001) than OAR patients. However, the extended hospital stay of patients who underwent EVAR had lower costs in all categories compared with the extended length of stay of those who underwent OAR. Mortality associated with EVAR was costlier than OAR associated mortality (mean $72,483 vs $59,804; P = .017). From 2009 to 2014, the mean total cost of EVAR increased significantly by 18.5% ($28,745 vs $34,049; P < .001) owing to a 7.8% increase in fixed costs ($10,931 vs $11,789; P < .001) and a 25.0% increase in variable costs ($17,804 vs $22,257; P < .001). The mean total cost OAR remained stable over time. CONCLUSIONS: Overall hospitalization costs associated with EVAR of non-rAAA was lower than the hospitalization cost of OAR. Interestingly, we found that, among patients who had an expected hospital length of stay, the hospitalization cost after OAR was significantly lower than after EVAR. The average hospitalization cost of OAR was stable during the 5 years study period, whereas the hospitalization cost of EVAR increased significantly over time. Further studies are required to identify reasons for increased costs associated with EVAR.
引用
- Gupta AK, Alshaikh HN, Dakour-Aridi H, et al. Real-world cost analysis of endovascular repair versus open repair in patients with nonruptured abdominal aortic aneurysms. J Vasc Surg. 2019. PMID: 31171423. doi:10.1016/j.jvs.2018.12.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。